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Abstract
Background: The QuantiFERONH-TB Gold In-Tube test (QFT-GIT) is a viable alternative to the tuberculin skin test (TST) for
detecting Mycobacterium tuberculosis infection. However, within-subject variability may limit test utility. To assess variability,
we compared results from the same subjects when QFT-GIT enzyme-linked immunosorbent assays (ELISAs) were performed
in different laboratories.
Methods: Subjects were recruited at two sites and blood was tested in three labs. Two labs used the same type of
automated ELISA workstation, 8-point calibration curves, and electronic data transfer. The third lab used a different
automated ELISA workstation, 4-point calibration curves, and manual data entry. Variability was assessed by interpretation
agreement and comparison of interferon-c (IFN-c) measurements. Data for subjects with discordant interpretations or
discrepancies in TB Response .0.05 IU/mL were verified or corrected, and variability was reassessed using a reconciled
dataset.
Results: Ninety-seven subjects had results from three labs. Eleven (11.3%) had discordant interpretations and 72 (74.2%) had
discrepancies .0.05 IU/mL using unreconciled results. After correction of manual data entry errors for 9 subjects, and
exclusion of 6 subjects due to methodological errors, 7 (7.7%) subjects were discordant. Of these, 6 (85.7%) had all TB
Responses within 0.25 IU/mL of the manufacturer’s recommended cutoff. Non-uniform error of measurement was observed,
with greater variation in higher IFN-c measurements. Within-subject standard deviation for TB Response was as high as
0.16 IU/mL, and limits of agreement ranged from 20.46 to 0.43 IU/mL for subjects with mean TB Response within 0.25 IU/
mL of the cutoff.
Conclusion: Greater interlaboratory variability was associated with manual data entry and higher IFN-c measurements.
Manual data entry should be avoided. Because variability in measuring TB Response may affect interpretation, especially
near the cutoff, consideration should be given to developing a range of values near the cutoff to be interpreted as
‘‘borderline,’’ rather than negative or positive.
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Introduction
Interferon gamma (IFN-c) release assays (IGRAs) are designed
to detect both latent Mycobacterium tuberculosis infection (LTBI) and
infections manifesting as active tuberculosis disease, collectively
referred to as M. tuberculosis infection (MtbI). IGRAs are a popular,
viable, and often preferred alternative to the traditional tuberculin
skin test (TST) in some settings [1–3]. Despite inadequacies in
diagnostic standards for identifying MtbI, numerous studies have
assessed the sensitivity and specificity of IGRAs [2–4]. However,
few studies have assessed the within-subject variability of IGRA
results. Within-subject variability includes differences in test results
due to both subject fluctuations and test performance fluctuations.
Excessive variability in IGRA results may limit their utility for
detecting MtbI. A limited number of studies have assessed IGRA
variability among people where treatment might affect serial test
results [5–9] or among contacts, healthcare workers (HCW), or
residents of high-TB burden countries where ongoing transmission
may affect serial IGRA results [10–24]. Rarely have investigators
examined variability due solely to test performance fluctuations on
blood collected at the same time [13,20]. No published
investigation has addressed variability when IGRAs are performed
in different laboratories on blood collected at the same time.
The QuantiFERONH-TB Gold In-Tube test (QFT-GIT,
Cellestis Limited, Carnegie, Victoria, Australia) is one of two
commercially available IGRAs currently in use in the U.S. The
goal of this study was to determine the within-subject variability of
the QFT-GIT when performed in different laboratories on blood




The Centers for Disease Control and Prevention (CDC) and
Wilford Hall Medical Center human subjects institutional review
boards approved this study. All subjects provided written informed
consent.
Subject Selection
Subjects were recruited from among Air Force and CDC staff
located in San Antonio, Texas, and Atlanta, Georgia, respectively,
as part of a larger study investigating parameters that affect QFT-
GIT variability. Prior unpublished assessments among a similar
cohort found a broad range of IFN-c measurements, and that 40%
to 50% of persons with self-reported prior positive TST results were
positive by QFT-GIT as compared to ,3% for the general U.S.
population. To increase the proportion of subjects with positive
QFT-GIT results and to assess subjects with a continuous range of
IFN-c measurements, including those with IFN-c measurements
near the cutoff separating positive and negative interpretations, only
persons with self-reported prior positive TST results were recruited.
Exclusion criteria were age of less than 18 years or a history of an
adverse reaction to TST (e.g., blistering, scarring, or anaphylaxis).
All subjects completed a detailed study questionnaire.
QFT-GIT Procedure
Blood from each subject was collected at a single sitting into
three sets of QFT-GIT tubes so that the assay could be completed
in three different labs (Lab1, Lab2, and Lab3), all with extensive
experience and demonstrated proficiency. Approximately 1 mL of
blood was collected into three tubes containing only heparin (Nil
tube); three tubes containing heparin, dextrose, and the mitogen
phytohemagglutinin A (Mitogen tube); and three tubes containing
heparin, dextrose, and Mtb antigens (TB Antigen tube). Mtb
antigens consisted of a single mixture of peptides representing
ESAT-6, CFP-10, and TB7.7 as described in the package insert.
Tubes with identical lot numbers were used. Tube contents were
mixed with a Stuart rock-and-roll mixer (SciTech Instruments,
Inc., Franklin, NJ) for 3 minutes at 33 RPM with the tube cap end
lowered 20u to ensure that the entire inner surface of each tube
was covered with blood. Within 1 hour of collection, the tubes
were placed upright in an incubator at 37+/20.5uC. The tubes
were incubated for 23 to 24 hours, after which they were
centrifuged at 3,000 g for 10 minutes. Centrifuged tubes were
stored and shipped at 2uC to 8uC. Temperatures during
incubation, storage, and shipping were confirmed with a SL300
temperature data logger (SupCo, Allenwood, NJ). The IFN-c
concentrations in plasmas from the Nil tube, the TB Antigen tube,
and the Mitogen tube (abbreviated Nil, TB, and Mitogen,
respectively) were determined by enzyme-linked immunosorbent
assay (ELISA), performed 13 to 15 days after blood collection
using reagents included in QFT-GIT kits. No attempt was made to
assure that QFT-GIT ELISA kits had identical lot numbers. All
test parameters were within specifications stipulated in the QFT-
GIT package insert. The TB Response was calculated by
subtracting Nil from TB, and Mitogen Response was calculated
by subtracting Nil from Mitogen.
Lab1 and Lab2 performed ELISAs with the aid of Triturus
automated ELISA workstations (Grifols USA, Inc., Miami, FL)
and used eight IFN-c standard calibrators (8, 4, 2, 1, 0.5, 0.25,
0.125, and 0 IU/mL) in duplicate to create standard curves. In
contrast, Lab3 performed ELISAs with the aid of a DSX
automated ELISA workstation (Dynex Technologies, Chantilly,
VA) and used four IFN-c standard calibrators (4, 1, 0.25, and
0 IU/mL) in duplicate to create standard curves after local
validation of the method. Raw optical density (OD) values were
transferred electronically at Lab1 and Lab2 and manually entered
at Lab3. Plasma IFN-c concentrations were determined using
software developed by Cellestis (QuantiFERONH-TB Gold In-
Tube Analysis Software v2.17.2) and with a Microsoft Access 2007
v12 database (Microsoft, Inc., Seattle, WA), developed at the
CDC. The CDC database differs from the software provided by
Cellestis in that INF-c concentrations were not truncated at
10 IU/mL or rounded prior to subtracting Nil to determine TB
Response and Mitogen Response.
Test results were interpreted as indicated in the Cellestis
package insert and CDC guidelines [2,25]. The interpretation was
‘‘positive’’ if the Nil was #8.0 IU/mL and the TB Response was
$0.35 IU/mL and $25% of the Nil. The interpretation was
‘‘negative’’ if the Nil was #8.0 IU/mL, the Mitogen Response was
$0.5 IU/mL, and the TB Response was ,0.35 IU/mL or ,25%
of the Nil. The interpretation was ‘‘indeterminate’’ if (a) the Nil
was .8.0 IU/mL or (b) the Nil was #8.0 IU/mL, the Mitogen
Response was ,0.5 IU/mL, and the TB Response was
,0.35 IU/mL or ,25% of the Nil. For subjects with discordant
interpretations, discrepancies in TB Response .0.05 IU/mL, or
unusual IFN-c measurements [26], results were recalculated based
on verified OD values entered directly from the ELISA reader
printout and used to create a reconciled dataset.
Statistical Methods
For assessment of variability in test interpretations (variability in
qualitative results), the percentage of subjects with concordant
results from tests performed at the three different labs was
determined. For each pair of labs, positive agreement, negative
agreement, and agreement beyond chance (Cohen’s kappa
statistic) were calculated. For the assessment of variability in
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quantitative results, Nil, TB, and TB Response distributions were
compared using the Wilcoxon signed-rank test. Five additional
indices of quantitative variability, the last two of which were
derived from the standard deviation of the differences (SDdiff),
were examined including (1) within-subject coefficient of variation
(W-S CV%), (2) intraclass correlation coefficient (ICC), (3) mean
difference between two labs (bias), (4) the smallest detectable
difference (SDD), and (5) the within-subject standard deviation
(W-S SD). SDD = 1.96*SDdiff and is the smallest change in a
second measurement that must occur to detect a change above the
variability (e.g., noise) with 95% confidence [27,28]. W-S
SD = 6(SDdiff/!2) [29] and represents 68% of the variation
expected around the true value [30]. Limits of agreement
(LOA) = bias 6 SDD and encompass the range around the bias
that contains 95% of within-subject differences [31]. ICCs were
calculated using the SAS macro ICC_SAS [32]. W-S CV% was
calculated as described by Bland (root mean square approach) [33]
for Nil and TB but estimated for TB Response using the formula
![(W-S CV%TB)2+(W-S CV%Nil)2]. The W-S CV%s for the TB
Response could not be directly determined due to inflation caused
by zeroes and low means in the denominator (a result of subjects
with both positive and negative TB Response values). A
confidence level of 0.95 was used in all hypothesis tests. Stratified
analyses for quantitative indices were performed on concordant
positive, concordant negative, and discordant groups and three
groups stratified by mean TB Response of ,0.10 IU/mL, 0.10
through 0.60 IU/mL, and .0.60 IU/mL. Indices of variability
were not reported for groups with less than 10 subjects to avoid
inaccuracies due to small sample size. SAS v9.2 (SAS, Cary, NC)
and ‘‘Analyse-It’’ v2.22 for Excel (Analyse-It Software, Ltd.,
Leeds, UK) were used to perform the analyses.
Results
Subject Characteristics
Study participation is depicted in Figure 1. Of the 174 people
asked to participate, 103 consented, and 97 had QFT-GIT tests
completed in all three labs. Characteristics of study subjects are
shown in Table 1.
Qualitative Results Using Original Data
Comparisons of test interpretations among all three labs using
original (unreconciled) data are shown in Table 2. No QFT-GIT
result was indeterminate. Eleven of 97 subjects (11.3%) had
discordant results. Comparisons of test interpretations between
Figure 1. Study participation diagram.
doi:10.1371/journal.pone.0043790.g001
Table 1. Subject characteristics.
Characteristic Category n (%)





Gender M 47 (48.5%)
F 50 (51.5%)
Race/Ethnicity White, non-Hispanic 46 (47.4%)
Black, non-Hispanic 19 (19.6%)
Hispanic 15 (15.5%)
Asian/Pacific 13 (13.4%)
Native American 0 (0.0%)
Other 4 (4.1%)






Received Therapy for TB Yes 2 (2.1%)
No 95 (97.9%)
Received Therapy for LTBI Yes 78 (80.4%)
No 19 (19.6%)
Known Exposure to Active TB Yes 36 (37.1%)
No/Unknown 61 (62.9%)
Received BCG Vaccine Yes 22 (22.7%)
No/Unknown 75 (77.3%)
Region of Birth United States and Canada 66 (68.0%)
Central America/Caribbean 9 (9.3%)
Asia 7 (7.2%)




Middle East 2 (2.1%)
South America 1 (1.0%)
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pairs of labs are shown in Table 3. Discordance ranged from 5.2%
to 10.4% using original data. Nil concentrations, TB Responses,
and QFT-GIT interpretations are shown in Table S1 for the 11
subjects with discordant interpretations using original data. Of
these 11 subjects, 4 (36.4%) had all TB Responses within 0.25 IU/
mL of the 0.35 IU/mL cutoff.
Quantitative Results Using Original Data
Median and mean Nil, TB, and TB Response values using
original data are shown in Table 4. Seventy-two (74.2%) subjects
had discrepancies in TB Response .0.05 IU/mL. One subject
had all three Nil values .0.7 IU/mL and three other subjects had
at least one NIL value .0.4 IU/mL. No subjects had TB
Responses ,20.35 IU/mL or Mitogen Responses ,20.5 IU/
mL. Indices of quantitative variability in original Nil, TB, and TB
Response are shown in Table S2.
Recognition of Data Entry and Methodological Errors
No errors in electronically transferred data were identified. Two
types of manual data entry errors at Lab3 were identified, affecting
results for nine subjects. The first type of error was a misalignment
of results for eight subjects so that TB, Nil, and TB Response
values were assigned to the wrong subjects. The second type of
error, affecting a ninth subject, occurred as a result of a misplaced
decimal point due to human error that caused inaccuracy in
reported TB and TB Response values. A line listing of QFT-GIT
results from these nine subjects is shown in Table S3. These errors
were corrected in the reconciled dataset. A third type of error was
recognized for six subjects who had extremely high IFN-c
concentrations reported for TB values in Lab3 (range 37.4 to
102.5 IU/mL) when compared to Lab1 and Lab2 (range 8.6 to
18.4 IU/mL) and when compared to other Lab3 TB values (all
.7 times the interquartile range of 3.33 IU/mL). TB and TB
Response values for these six subjects and a seventh subject with
the next highest Lab3 TB and TB Response values are shown in
Table S4. The large discrepancies and high TB values reported by
Lab3 were due to misinterpreted OD values reported by the
ELISA workstation. OD values above the working range of the
Lab3 reader were reported as ‘‘9.999’’, resulting in calculation of
exaggerated and inaccurate IFN-c concentrations. This was a
methodological error. OD values above the working range were
reported in the other labs as ‘‘OWR’’ (outside of working range),
thus preventing calculation of an IFN-c concentration. Because
the ODs reported as ‘‘9.999’’ could not be verified for the six
subjects with exaggerated TB values, data from these six subjects
were excluded from the reconciled dataset.
Qualitative Results Using Reconciled Data
Comparisons of test interpretations among all three labs using
reconciled data are shown in Table 2. No QFT-GIT result was
indeterminate. Seven of 91 subjects (7.7%) had discordant results
after data were reconciled. Comparisons of test interpretations
between pairs of labs are shown in Table 3 using reconciled data.
Nil concentrations, TB Responses, and QFT-GIT interpretations
are shown in Table S1 for the 7 subjects with discordant
interpretations using reconciled data. Of these seven, six (85.7%)
had all TB Responses within 0.25 IU/mL of the 0.35 IU/mL
cutoff. Of 12 subjects who had one or more TB Responses within
0.25 IU/mL of the cutoff, 7 (58.3%) had discordant QFT-GIT
interpretations, while none of the 72 subjects with no TB Response
in this range had discordance.
Quantitative Results Using Reconciled Data
Median and mean Nil, TB, and TB Response values using
reconciled data are shown in Table 4. NIL values .0.4 IU/mL
did not change. No subjects had TB Responses ,20.35 IU/mL
or Mitogen Responses ,20.5 IU/mL. Examination of the
reconciled data with Bland-Altman difference plots (Figure 2)
Table 2. Summary comparisons of QuantiFERON-TB Gold In-Tube test interpretations performed on the same subjects in three
labs.
Results compared n All 3 positive All 3 negative
2 positive & 1
negative




Lab1, Lab2, & Lab3 (original data) 97 39 47 6 5 11 (11.3%)
Lab1, Lab2, & Lab3 (reconciled data) 91 35 49 4 3 7 (7.7%)
doi:10.1371/journal.pone.0043790.t002









negative Positive*/negative Negative*/positive Overall Positive Negative Overall Kappa
Lab1 vs. Lab2 (original data) 42 50 3 2 94.8 89.4 90.9 5.2 0.90
Lab1 vs. Lab3 (original data) 40 47 5 5 89.7 80.0 82.5 10.4 0.79
Lab2 vs. Lab3 (original data) 41 49 3 4 92.8 85.4 87.5 7.2 0.85
Lab1 vs. Lab2 (reconciled data) 36 50 3 2 94.5 87.8 90.9 5.5 0.89
Lab1 vs. Lab3 (reconciled data) 36 49 3 3 93.4 85.7 89.1 6.6 0.87
Lab2 vs. Lab3 (reconciled data) 37 51 1 2 96.7 92.5 94.4 3.3 0.93
* = Group1/Group2.
doi:10.1371/journal.pone.0043790.t003
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showed that variation increased as the mean of the paired
measurements increased. For this reason, stratified analyses were
performed. Among concordant negatives, TB Responses in Lab3
were significantly greater than in Lab1 (p,0.001, Wilcoxon
signed-rank test) or Lab2 (p = 0.002). TB values followed a similar
pattern (p = 0.01 and 0.001, respectively). Among concordant
positives, TB and TB Responses in Lab2 were significantly greater
than in Lab3 (p = 0.01 for both). No significant differences were
seen for any of the Nil comparisons.
Indices of quantitative variability in reconciled Nil, TB, and TB
Response values are shown in Table 5. Bias and LOA showed
greater variability in TB Response among subjects with concor-
dant positive interpretations than those with concordant negative
interpretations. Bias in TB Response ranged from 0.00 IU/mL
when data from Lab1 and Lab2 were compared for subjects with
concordant negative interpretations to 1.82 IU/mL when data
from Lab1 and Lab3 were compared for subjects with concordant
positive interpretations. SDD ranged from 0.08 to 9.61 IU/mL in
these groups, respectively. Indices for TB Response variability
tracked indices of variability for TB. Nil values were less variable
between strata and between labs than TB or TB Response values.
W-S SD followed a similar trend with variability of concordant
positives . variability of total population . variability of
concordant negatives. Examination of ICC revealed that concor-
dant negatives were less correlated than concordant positives.
Variability adjusted for each subject’s mean value (W-S CV%) was
similar for subjects with concordant negative and concordant
positive results for Lab1 vs. Lab2, but much larger in concordant
negatives for TB and TB Response when Lab1 or Lab2 was
compared to Lab3.
Bias, upper and lower LOA, W-S SD, and their 95% confidence
intervals (CIs) for TB Response using an alternative stratification
scheme (,0.10 IU/mL, 0.10 to 0.60 IU/mL, and .0.60 IU/mL)
based on the subject’s mean value from the three labs are shown in
Table 6. These results indicate a similar trend of increasing
variability with increasing TB Response. The values for the middle
group (0.10 IU/mL to 0.60 IU/mL), are intended to provide an
estimate of the variability of TB Response surrounding the assay
cutoff. W-S SD for this group ranged from 60.08 IU/mL to
60.16 IU/mL with the largest upper 95% CI boundary for this
group being 0.25 IU/mL (Lab1 vs. Lab 2).
Comparison of Results Using Original and Reconciled
Data
Correction of the manual data entry errors for 9 subjects
changed the test interpretations for six subjects: from positive to
negative for three and from negative to positive for three (Table
S3). Table S1 shows that correcting manual data entry errors
resolved the discordance observed in the original results for five
subjects, but generated discordance for another subject. While
11.3% of subjects had discordant interpretations among the three
labs using original data, 7.7% had discordant interpretations using
reconciled data (Table 2). As shown in Table 3, of the Lab3
comparisons, those involving the original data showed lower
agreement than those involving reconciled data, while minimal
change was observed for Lab1 vs. Lab2, with lowering of the
denominator from 97 to 91. Removal of the six subjects with
extremely high Lab3 TB and TB Response values did not change
the number of subjects with discordant interpretations because
these six subjects were concordantly positive. While 36.4% of
subjects with discordance using original data had all TB Responses
within 0.25 IU/mL of the cutoff, 85.5% of those with discordance
using reconciled data had all TB Responses within 0.25 IU/mL of
the cutoff.
Table 4. Median and mean IFN-c measurements for QuantiFERON-TB Gold In-Tube tests performed on the same subjects in three
labs.
Source n Nil TB TB Response
Median Mean Median Mean Median Mean
Lab1 (original) unstratified 97 0.07 0.10 0.27 4.11 0.15 4.01
Lab2 (original) unstratified 97 0.06 0.09 0.24 3.88 0.19 3.79
Lab3 (original) unstratified 97 0.07 0.11 0.40 5.92 0.26 5.81
Lab1 (reconciled)
Unstratified * 91 0.07 0.09 0.18 3.11 0.08 3.01
Concordant Positive{ 35 0.07 0.11 3.93 7.85 3.31 7.74
Concordant Negative1 49 0.07 0.08 0.08 0.10 0.01 0.02
Lab2 (reconciled)
Unstratified * 91 0.06 0.09 0.16 2.91 0.09 2.83
Concordant Positive{ 35 0.07 0.11 4.47 7.37 4.23 7.26
Concordant Negative1 49 0.06 0.07 0.08 0.09 0.01 0.02
Lab3 (reconciled)
Unstratified * 91 0.07 0.11 0.32 2.94 0.18 2.33
Concordant Positive{ 35 0.07 0.12 3.72 6.04 3.25 5.91
Concordant Negative1 49 0.07 0.10 0.11 0.14 0.02 0.05
Nil = IFN-c concentrations (IU/mL) in plasma from the Nil tube of the QuantiFERON-TB Gold In-Tube test (QFT-GIT); TB = IFN-c concentrations (IU/mL) in plasma from the
TB tube of QFT-GIT; TB Response = TB minus Nil.
*Includes 7 subjects with discordant QFT-GIT interpretations.
{Concordant positive among results from all 3 labs.
1Concordant negative among results from all 3 labs.
doi:10.1371/journal.pone.0043790.t004
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Quantitative indices of test variability were lowered by
correcting the data entry errors. Comparison of quantitative
results of original and reconciled data showed that Lab3 median
and mean TB and TB Response values decreased following
correction of the misplaced decimal point and exclusion of the six
subjects with exaggerated TB and TB Response values (Table 4).
Median and mean TB and TB Response values for Lab1 and
Lab2 also decreased with exclusion of these six subjects.
Quantitative variability in TB and TB Response values decreased
with data reconciliation as demonstrated by reductions in LOA,
W-S SD, ICC, and W-S CV% when unstratified results from each
pair of labs were compared using original data (Table S2) versus
reconciled data (Table 5).
Discussion
We observed substantial within-subject interlaboratory variabil-
ity in QFT-GIT interpretations and IFN-c measurements when
blood samples collected from the same person at the same time
were tested in three different labs. Of the 97 subjects tested in
three labs, 11% had discordant QFT-GIT interpretations based
on the original reported data. Electronic transfer of data was not
possible for one of the three labs testing specimens for this study,
and a portion of the variability in test interpretation was associated
with manual data entry errors. Data entry errors included data
misalignments and a misplaced decimal point that were encoun-
tered with manual data entry but not electronic data transfers. All
three labs used an automated ELISA workstation to assist in
performing QFT-GIT, and this may have avoided additional data
entry errors. As compared to manually performed ELISAs,
automated ELISA workstations can read specimen barcodes that
discriminate subjects and QFT-GIT tube type (i.e., Nil tube, TB
Antigen tube, Mitogen tube) and assign OD values to specific
specimens. This avoids some inaccuracies that have been
attributed in prior studies to data entry errors and transposition
of IFN-c measurements [26].
A third type of error was recognized for six subjects who had
exaggerated TB values in one lab due to errors in interpreting OD
values when they were over the working range of the ELISA
workstation. Certain lots of ELISA kits with higher activity as
evidenced by higher OD values for standards tended to have
higher ODs for plasma samples and have more TB ODs above the
working range for the ELISA readers (data not shown). Data from
the six subjects with OD values over the working range were
excluded from the reconciled dataset. Removal of these subjects
with methodological errors did not appreciably alter interpretation
agreement because all were concordantly positive.
Corrections of data entry errors made a substantial difference in
interpretative agreement between each lab and among all three labs.
When reconciled data from Lab1 vs. Lab2, Lab1 vs. Lab3, or Lab2
vs. Lab3 were compared, 94.5%, 93.4%, and 96.7% of interpre-
tations agreed, respectively. However, among all three labs, 92.3%
of subjects had concordant results after the data were reconciled.
Several pieces of evidence suggest that the majority of
discordance in QFT-GIT interpretation remaining after data
reconciliation was due to variability in measuring TB Response.
While none of the subjects with discordance attributed to data entry
errors had all TB Response values within 0.25 IU/mL of the cutoff
separating positive and negative interpretations, 86% of those with
discordance after data were reconciled had all TB Response values
within this range. Additionally, 37% of the subjects who had one or
more TB Response values within this range after data were
reconciled had discordance, but none of the subjects without a TB
response within this range had discordance. These statistics do not
describe the actual magnitude of variability in TB Response.
We examined the magnitude of variability in TB Response and
the two IFN-c measurements used to calculate TB Response. Of
Figure 2. Difference (Bland-Altman) plots. Difference (Bland-Altman) plots for Nil (panel A) and TB (panel B). Differences (y-axis) and means of
pairs (x-axis) are in IU/mL IFN-c.
doi:10.1371/journal.pone.0043790.g002
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the many indices of variability, LOA may be the most informative.
LOA is expressed in units of test measurement and includes bias.
W-S CV% masks the impact of IFN-c concentration magnitude
on variability, while ICC and W-S SD do not take into account the
bias between measurements. Variability, as measured by LOA,
was greater for higher IFN-c measurements. This was observed for
Nil, TB, and TB Response, but because TB and TB Response
values tended to be larger than Nil values, greater variability was
Table 5. Variability in Quantiferon-TB Gold in-Tube test measurements performed on the same subjects in three labs excluding
those with extremely high TB Response.
LOA*
Measure Comparison n Bias*{ ± (SDD*) W-S SD* (95%CI) ICC (95% CI) W-S CV% (95% CI)
Nil
Lab1 vs. Lab2
Unstratified1 91 0.016(0.11) 60.04 (0.03, 0.04) 0.89 (0.84, 0.93) 33.63 (29.38, 37.40)
Concordant Positive# 35 0.006(0.12) 60.04 (0.04, 0.06) 0.94 (0.89, 0.97) 35.11 (28.53, 40.63)
Concordant Negative‘ 49 0.016(0.10) 60.04 (0.03, 0.05) 0.22 (20.06, 0.47) 33.56 (27.08, 38.98)
Lab1 vs. Lab3
Unstratified1 91 20.016(0.16) 60.06 (0.05, 0.07) 0.72 (0.61, 0.81) 40.83 (35.50, 45.54)
Concordant Positive# 35 20.016(0.17) 60.06 (0.05, 0.08) 0.86 (0.74, 0.93) 40.47 (30.89, 48.18)
Concordant Negative‘ 49 20.026(0.16) 60.06 (0.05, 0.07) 0.13 (20.15, 0.39) 41.91 (34.54, 48.16)
Lab2 vs. Lab3
Unstratified1 91 20.026(0.19) 60.07 (0.06, 0.08) 0.64 (0.50, 0.75) 44.78 (38.78, 50.06)
Concordant Positive# 35 20.016(0.22) 60.08 (0.06, 0.10) 0.78 (0.61, 0.88) 44.11 (36.00, 50.93)
Concordant Negative‘ 49 20.026(0.17) 60.06 (0.05, 0.08) 20.14 (20.40, 0.14) 46.54 (37.31, 54.21)
TB
Lab1 vs. Lab2
Unstratified1 91 0.196(2.98) 61.08 (0.94, 1.26) 0.97 (0.96, 0.98) 28.23 (22.40, 33.05)
Concordant Positive# 35 0.486(4.79) 61.73 (1.40, 2.27) 0.96 (0.92, 0.98) 23.14 (16.98, 27.97)
Concordant Negative‘ 49 0.006(0.09) 60.03 (0.03, 0.04) 0.69 (0.51, 0.81) 26.07 (20.30, 30.77)
Lab1 vs. Lab3
Unstratified1 91 0.676(6.18) 62.23 (1.95, 2.61) 0.84 (0.77, 0.89) 37.43 (32.06, 42.12)
Concordant Positive# 35 1.816(9.62) 63.47 (2.81, 4.55) 0.76 (0.58, 0.87) 31.32 (25.36, 36.32)
Concordant Negative‘ 49 20.046(0.19) 60.07 (0.06, 0.09) 0.39 (0.13, 0.60) 39.89 (31.87, 46.55)
Lab2 vs. Lab3
Unstratified1 91 0.486(4.28) 61.54 (1.35, 1.81) 0.91 (0.87, 0.94) 35.37 (29.77, 40.19)
Concordant Positive# 35 1.336(6.61) 62.38 (1.93, 3.12) 0.85 (0.73, 0.92) 26.99 (19.91, 32.57)
Concordant Negative‘ 49 20.056(0.20) 60.07 (0.06, 0.09) 0.32 (0.05, 0.55) 40.57 (32.31, 47.42)
TB Response
Lab1 vs. Lab2
Unstratified1 91 0.196(2.97) 61.07 (0.94, 1.26) 0.97 (0.96, 0.98) 43.91 (36.95, 49.91)
Concordant Positive# 35 0.486(4.77) 61.72 (1.39, 2.26) 0.96 (0.92, 0.98) 42.04 (33.20, 49.32)
Concordant Negative‘ 49 0.006(0.08) 60.03 (0.03, 0.04) 0.70 (0.53–0.82) 42.49 (33.84, 49.66)
Lab1 vs. Lab3
Unstratified1 91 0.686(6.17) 62.23 (1.94, 2.61) 0.84 (0.77, 0.89) 55.39 (47.83, 62.03)
Concordant Positive# 35 1.826(9.61) 63.47 (2.80, 4.54) 0.76 (0.58, 0.87) 51.17 (39.96, 60.33)
Concordant Negative‘ 49 20.036(0.11) 60.04 (0.03, 0.05) 0.56 (0.34, 0.72) 57.86 (47.00, 66.98)
Lab2 vs. Lab3
Unstratified1 91 0.506(4.29) 61.55 (1.35, 1.81) 0.91 (0.87, 0.94) 57.06 (48.89, 64.20)
Concordant Positive# 35 1.356(6.64) 62.40 (1.94, 3.14) 0.85 (0.73, 0.92) 51.71 (41.14, 60.46)
Concordant Negative‘ 49 20.036(0.11) 60.04 (0.03, 0.05) 0.63 (0.43, 0.77) 61.74 (49.35, 72.03)
*LOA, bias, SDD, and W-S SD are in IU/mL of IFN-c.
{Directionality for bias and LOA comparisons: Lab1-Lab2, Lab1-Lab3, Lab2-Lab3.
1Includes 7 subjects with discordant QFT-GIT interpretations.
#Concordant positive among results from all 3 labs.
‘Concordant negative among results from all 3 labs.
doi:10.1371/journal.pone.0043790.t005
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observed in TB and TB Response, especially for subjects with
concordant positive interpretations. Because TB Response is
calculated from two measurements, its variability could be greater
than the variability in measurements used in the calculation (i.e.,
TB and Nil). Additionally, because Nil and TB are measured in
the same ELISA, subtraction of Nil from TB could reduce
variability in TB Response by compensating for interassay bias if
the bias was constant regardless of the level of IFN-c measured.
However, we observed that (1) the bias in measuring IFN-c
concentration was not constant, (2) the variability in TB Response
tracked the variability in TB, and (3) subtracting Nil did not fully
compensate for variability in TB when calculating TB Response.
Another reason for lower quantitative variability for people with
negative results is that the TB Response is constrained to a
relatively small range (typically ,0.35 IU/mL) compared to the
TB Response for those with positive results.
While subjects with concordant positive interpretations had
more variability in TB Response than those with concordant
negative interpretations, the variability near the cutoff is of greater
importance because of its effect on interpretive agreement. Bland-
Altman analysis allows assessment of variability in paired
measurements and identifies the range of measurements encom-
passing 95% of TB Response variability associated with repeat
testing. Because variability is not uniform across the range of TB
Response values, applying a global measure of variability derived
from the entire range may not be suitable near the cutoff. Among
the 14 subjects with a mean TB Response of 0.10 through
0.60 IU/mL (i.e., 0.3560.25 IU/mL), which included 6 of the 7
subjects with discordant QFT-GIT interpretations, the upper
LOA was as high as 0.43 IU/mL and the lower LOA was as low
as 20.46 IU/mL (Table 6). The 95% CIs for LOAs may be
relatively large because of the small number of subjects with mean
TB Response values near the cutoff. Clinicians, naive to the
direction of comparison, can expect results from a second lab to be
within 0.46 IU/mL of the first with 95% certainty. Because this
estimate of variability is determined for a range (i.e., 0.10 through
0.60 IU/mL), it overestimates variability for TB Response values
near 0.10 IU/mL and underestimates variability for TB Response
values near 0.60 IU/mL. Another consideration is that for a
particular TB Response, changes in only one direction can alter
test interpretation.
The amount of uncertainty in interpreting QFT-GIT that is
acceptable has not been established. Whereas LOA encompasses a
range for 95% of the test-retest differences, bias 6 W-S SD
encompasses 52% of the variability expected with retesting [30]. W-
S SD also reflects the variability relative to the true value such that
68% of measurements will be within one W-S SD of the theoretical
true value (typically estimated as the subject’s mean value) [30]. W-S
SD for TB Response was as high as 0.16 IU/mL for subjects with
mean TB Response near the cutoff (i.e., 0.10 through 0.60 IU/mL).
W-S SD, which is also referred to as ‘‘wobble’’, is intended to
describe random variation. What we measured as interlaboratory
bias could be misinterpreted as random variation if testing were
performed in a random selection of laboratories.
We harmonized testing methods as much as possible, so that there
were no differences in delays to incubation, incubation time,
incubation temperature, and minimal differences in duration of
storage. However, there were areas where consistency could not be
maintained. For example, labs used QFT-GIT kits with different lot
numbers, different automated ELISA workstations, different cali-
bration curves, and different reporting methods. Greater variability
may have occurred with less harmonization of test methods.
Various borderline zones around the cutoff have been proposed to
address variability [14,15,18–20,34]. However, prior investigations
have not considered interlaboratory variability or the impact of non-
uniform variability in measuring TB Response. Most prior
investigations of variability have been challenged to analyze relatively
small sample sizes. The small number of subjects near the cutoff also
challenged our stratified analysis. Despite the lack of available data
from interlaboratory reproducibility studies, our estimates of
discordance (11.3% to 7.7%) seem to be in keeping with those seen
in intralaboratory between-run estimates of discordance [13,18–20].
Interlaboratory variability is a symptom of a larger problem of
IGRA imprecision. IGRA imprecision may also explain a portion
of the variability encountered with serially performed IGRAs
among healthcare workers [10–24]. We measured test variation
that is not attributable to subject variation (e.g., due to new
infection, treatment, or fluctuations in immune status). Blood
samples were collected at the same time to exclude the effect of
subject variation due to time. Additional studies are needed to
assess IGRA imprecision and understand the components of
variation seen in serial testing. The imprecision demonstrated with
Table 6. W-S SD, bias, and LOA in three strata based on the mean TB Response for Lab1, Lab2, and Lab3.
Comparison n Bias (95% CI) Lower LOA (95% CI) Upper LOA (95% CI) W-S SD (95% CI)
Lab1 vs. Lab2
mean* .0.60 34 0.50 (20.37, 1.36) 24.34 (25.84, 22.85) 5.33 (3.84, 6.83) 61.75 (1.41, 2.30)
mean* 0.10 to 0.60 14 0.00 (20.13, 0.12) 20.44 (20.66, 20.22) 0.43 (0.21, 0.65) 60.16 (0.11, 0.25)
mean* ,0.10 43 0.00 (20.01, 0.01) 20.07 (20.09, 20.05) 0.08 (0.06, 0.10) 60.03 (0.02, 0.04)
Lab1 vs. Lab3
mean* .0.60 34 1.88 (0.15, 3.61) 27.84 (210.84, 24.85) 11.61 (8.61, 14.61) 63.51 (2.83, 4.62)
mean* 0.10 to 0.60 14 20.08 (20.19, 0.03) 20.46 (20.65, 20.26) 0.30 (0.10, 0.49) 60.14 (0.10, 0.22)
mean* ,0.10 43 20.02 (20.03, 0.00) 20.10 (20.13, 20.08) 0.07 (0.04, 0.09) 60.03 (0.03, 0.04)
Lab2 vs. Lab3
mean* .0.60 34 1.39 (0.19, 2.58) 25.34 (27.41, 23.26) 8.11 (6.04, 10.18) 62.43 (1.96, 3.19)
mean* 0.10 to 0.60 14 20.07 (20.14, 20.01) 20.29 (20.40, 20.18) 0.14 (0.03, 0.25) 60.08 (0.06, 0.13)
mean* ,0.10 43 20.02 (20.03, 20.01) 20.11 (20.13, 20.08) 0.07 (0.04, 0.09) 60.03 (0.03, 0.04)
95% CI = 95% confidence interval; LOA = limit of agreement; W-S SD = within-subject standard deviation.
*Stratifications based on mean TB Response among all three labs.
doi:10.1371/journal.pone.0043790.t006
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serial testing and by interlaboratory variability is also relevant
when interpreting individual or initial IGRA results.
In conclusion, greater interlaboratory variability was associated
with manual data entry and higher IFN-c measurements. Manual
data entry should be avoided. Our data suggest that variability in
measuring TB Response may affect QFT-GIT interpretation,
especially when near the cutoff. Therefore, consideration should
be given to interpreting such responses as ‘‘borderline’’ rather than
negative or positive, and clinical decisions regarding treatment or
the need to repeat these tests should be based on individualized
clinical judgment considering the risk of infection, the risk of
disease, and the proximity of the TB Response to the cutoff. In the
population we studied, interpreting TB Response values of 0.10
through 0.60 as ‘‘borderline’’ would have avoided most changes in
test interpretation due to measurement variability. However, this
may not be the appropriate range for the entire population for
whom QFT-IT is recommended. Additional studies are needed to
determine the optimal range of values for borderline results and to
explore the impact of using a borderline interpretation.
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